安进一种自身免疫药物在后期临床试验达到主要目标

格隆汇09-24 10:32

安进公布，其用于治疗一种自身免疫性疾病的试验性药物，在后期临床试验中达到了降低疾病活动度的主要目标。试验结果显示，对于疾病活动度处于中重度水平的干燥综合征患者，药物dazodalibep在第48周时展现出了具有统计学意义和临床意义的改善效果。诺华和强生也在开发治疗干燥综合征的药物；目前，美国尚无获批用于治疗该疾病的药物。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2669453169?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-24 10:32","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2669453169","market":"us","top_or_hot":-1,"title":"安进一种自身免疫药物在后期临床试验达到主要目标","media":"格隆汇","content":"<html><body>安进公布，其用于治疗一种自身免疫性疾病的试验性药物，在后期临床试验中达到了降低疾病活动度的主要目标。试验结果显示，对于疾病活动度处于中重度水平的干燥综合征患者，药物dazodalibep在第48周时展现出了具有统计学意义和临床意义的改善效果。诺华和强生也在开发治疗干燥综合征的药物；目前，美国尚无获批用于治疗该疾病的药物。</body></html>","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安进一种自身免疫药物在后期临床试验达到主要目标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安进一种自身免疫药物在后期临床试验达到主要目标\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body>安进公布，其用于治疗一种自身免疫性疾病的试验性药物，在后期临床试验中达到了降低疾病活动度的主要目标。试验结果显示，对于疾病活动度处于中重度水平的干燥综合征患者，药物dazodalibep在第48周时展现出了具有统计学意义和临床意义的改善效果。诺华和强生也在开发治疗干燥综合征的药物；目前，美国尚无获批用于治疗该疾病的药物。</body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.gelonghui.com/rss/live/live.xml\">格隆汇</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2669453169","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669453169","pubTimestamp":1790217159,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"安进公布，其用于治疗一种自身免疫性疾病的试验性药物，在后期临床试验中达到了降低疾病活动度的主要目标。试验结果显示，对于疾病活动度处于中重度水平的干燥综合征患者，药物dazodalibep在第48周时展","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK4599":"减肥药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BIB":"Ultra纳斯达克生物科","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","PJP":"INVESCO PHARMACEUTICALS ETF","BK4566":"资本集团","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","MDTX":"Corgi MediaTek 2x Daily ETF","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","AMGN":"安进","PSYK":"PSYK ETF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","IBB":"生物科技指数ETF-iShares Nasdaq","BMED":"iShares Health Innovation Active ETF","LU0058720904.USD":"联博国际健康护理基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BBH":"VanEck Biotech ETF","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"An autoimmune drug from Amgen has reached its main goal in late-stage clinical trials.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PJP":0.6,"PSYK":1.5,"IBBQ":1.5,"PBE":0.6,"MDTX":1.5,"BIB":0.6,"IBBJ":1.5,"BBH":0.6,"IBB":0.6,"BMED":1.5,"AMGN":1.5,"TBXU":0.6},"content_text":"安进公布，其用于治疗一种自身免疫性疾病的试验性药物，在后期临床试验中达到了降低疾病活动度的主要目标。试验结果显示，对于疾病活动度处于中重度水平的干燥综合征患者，药物dazodalibep在第48周时展现出了具有统计学意义和临床意义的改善效果。诺华和强生也在开发治疗干燥综合征的药物；目前，美国尚无获批用于治疗该疾病的药物。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669453169","isCrawlerRequest":true}